Histopathological Study and Expression of CD 117 in Renal Cell Carcinoma

  • Rasmi Unnikrishnan Sree Narayana Institute of Medical Sciences, Ernamkulam, Kerala, India
  • Praseeda I Travencore Medical College, Kollam, Kerala, India
  • Santha Sadashivan Sree Mookambika Institute of Medical Sciences, Tamil Nadu, Kerala, India
Keywords: Renal Cell Carcinoma, Histopathological study, Immunohistochemistry


Background: Hypernephroma or Renal Cell Carcinoma (RCC) accounts for over 90% of all malignancies of the kidney occurring in adults. Of all renal cell carcinomas, Clear cell carcinoma accounts for around two-thirds to three-quarters  and  Chromophobe  RCC accounts for  around 5%. The present study highlights the diagnostic usefulness of CD117 as a phenotypic marker in Renal Cell Carcinoma. Methods: Current study include 48 cases of histopathology proven renal cell carcinoma. Each  case was reviewed and classified according to the WHO classification criteria. The expression of CD117 was assessed using immunohistochemistry. Result: Of the 48 cases studied, 6cases, that is 2 case of Papillary RCC and 3 case of  Chromophobe RCC showed moderate intensity and diffuse positivity for CD 117 and 1case of clear cell RCC with sarcomatoid areas showed mild and focal positivity. Papillary RCC showed both cytoplasmic and membrane positivity, while Chromophobe RCC showed mainly membranous positivity. Sarcomatoid areas showed weak cytoplasmic positivity. Conclusion: Histopathology supported by immunohistochemistry  is a helpful tool in subtyping the various RCC. Treatment options in advanced disease is minimal. CD 117 positivity may favour the use of targeted therapy in renal cell carcinomas.

Author Biographies

Rasmi Unnikrishnan, Sree Narayana Institute of Medical Sciences, Ernamkulam, Kerala, India
Department of Pathology
Praseeda I, Travencore Medical College, Kollam, Kerala, India
Department of Pathology
Santha Sadashivan, Sree Mookambika Institute of Medical Sciences, Tamil Nadu, Kerala, India
Department of Pathology


1.Rekha PR, Rajendiran S, Rao S, Shroff S, Joseph LD, Prathiba D. Histological reclassification , histochemical characterization and CD117 immunoexpression in RCC. J Urol. 2008 ;24(3):343-347
2.Siegel R, Naishadham D, and Jemal A. Cancer Statistics 2013; CA: A Cancer Journal for Clinicians. 2013 ; 63(1):11–30
3.Kato M, Suzuki T, Suzuki Y, Terasawa Y, Sasano H, Arai Y. Natural History of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J Urol. 2004 ;172(3):863-6
4.Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol. 2001 ;163(2):426-30.
5.Skinnider BF., Amin MB. An immunohistochemical approach to the differential diagnosis of renal tumors. Semin Diagn Pathol. 2005; 22 (1): 51-68.
6.Ahmed EA, and Youssif ME. Immunohistochemical Study of c-KIT (CD117) Expression in Renal Cell Carcinoma J Egyptian Nat. Cancer Inst. 2009 ; 21(2): 121-132.
7.Athar U, Gentile TC. Treatment options for metastatic renal cell carcinoma: a review. Can J Urol. 2008;15: 3954–3966.
8.1st EAU-ICUD - International Consultation on Kidney Cancer Barcelona-2010
9.Liu L, Qian J, Singh H, Meiers I, Zhou X, Bostwick DG. Immunohistochemical Analysis of Chromophobe Renal Cell Carcinoma, Renal Oncocytoma, and Clear Cell Carcinoma An Optimal and Practical Panel for Differential Diagnosis. Arch Pathol Lab Med. 2007;131:1290–1297
10.Stec R, Grala B, Mączewski M, Bodnar L and Szczylik C. Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease. Journal of Experimental & Clinical Cancer Research. 2009, 28:134
Original Article